News
-
According to Harm Reduction Therapeutics (HRT), the court handling the bankruptcy of Purdue Pharma has approved an additional $9 million in Purdue funds to be used by HRT to prepare for possible commercialization of RiVive… Read more . . .
-
Vistagen said that a Phase 3 open label safety study of fasedienol (PH94B, aloradine) nasal spray for the treatment of social anxiety disorder (SAD) found that up to 4 daily doses of 3.2 µg was well-tolerated,… Read more . . .
-
The DDL committee is currently taking submissions for conference papers, for the DDL Emerging Scientist Award (deadline June 30, 2023) and the Pat Burnell Young Investigator Award (deadline July 14, 2023). Submit conference papers through… Read more . . .
-
Firebrick Pharma announced that it is re-starting a Phase 3 clinical trial of Nasodine povidone-iodine nasal spray as the 2023 common cold season begins in the Southern Hemisphere. According to the company, the trial, which… Read more . . .
-
US start-up Allermi said that it has raised $3.5 million in a seed round led by Nelstone Ventures for “the world’s first custom approach offered by Allermi that combines and adjusts the doses of multiple… Read more . . .
-
The Stevanato Group has announced that it will manufacture pre-fillable glass syringes for Recipharm’s Resyca pre-filled syringe soft mist inhalers for the delivery of biologics. According to Stevanato Group, the interior of the Alba glass syringe… Read more . . .
-
RDD Europe 2023, organized by RDD Online and Aptar Pharma, returns to Antibes, France, May 2-5 at the Palais des Congrès Antipolis. Richard Dalby of RDD Online says that conference center (previously called the Palais… Read more . . .
-
Aridis Pharmaceuticals has announced that a Phase 2a study of the company’s AR-501 nebulized gallium in cystic fibrosis patients with P. aeruginosa lung infections met its primary and secondary endpoints, with all 3 dose levels tested being well… Read more . . .
-
ReCode Therapeutics said that it has initiated a Phase 1 clinical trial of its RCT1100 nebulized mRNA-based therapeutic, which the company is developing for the treatment of primary ciliary dyskinesia (PCD) caused by certain genetic… Read more . . .
-
The Lonza Small Molecules facility in Tampa, FL, USA has upgraded its powder analysis capabilities, the company said. In May 2022, Lonza announced that it was expanding its dry powder testing facilities in Tampa in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.